-+ 0.00%
-+ 0.00%
-+ 0.00%
Aclaris Phase 2 ADMIRATION Trial Of Anti-TSLP Antibody Bosakitug In Atopic Dermatitis Misses Primary Endpoint Of EASI Percent Change At Week 24, Secondary Endpoints Also Not Met
Share
Listen to the news

- The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 -

- Aclaris Remains Focused on Prioritizing the Development of its Oral Kinase (ITK) Inhibitors and Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 -

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending